After three rounds of collection, the out-of-hospital market has become a new battleground for multinational pharmaceutical companies

"Pharmaceutical network industry dynamics" after the third batch of harvesting, "transnational pharmaceutical companies almost collective departure" has become the industry's common talk, with the previous second collection and local enterprises desperately kill the difference is significant, foreign pharmaceutical companies only three finalists, respectively, Pfizer, Eiswei, Ukip;
It is worth noting that the third round of national multinational pharmaceutical companies in addition to the winning bid less, a number of multinational pharmaceutical companies quotation decline is also small, such as Merca Dong original research chloreta fixed oral regular release agent type to exceed the limit price of 1.56 times out, Roche original research capabin oral regular release agent type to exceed the limit price of 2.23 times out ... In fact, the price reduction is expected, and foreign pharmaceutical companies collective "self-deprecating" quotations have long been followed.
years, with the first two rounds of volume procurement continue to deepen, has become an inevitable trend in the industry, it has long been widely accepted.
And many multinational pharmaceutical companies have also made it clear that in the Chinese hospital market exclusive expired original research drugs to get the 'luxury version' price is not possible, need to think about the winning bid, how to balance the market price inside and outside the hospital;
From this third round of collection before and after the action of multinational pharmaceutical companies can clearly see that its strategy adjustment war has begun, "in the domestic layout of innovative drugs, turn to the out-of-hospital market" and other actions have also begun to appear.
, multinational pharmaceutical companies in the domestic layout of innovative drugs, one is with the local Biotech "hug", the other is to establish research and development centers in China.
incomplete statistics show that MNC's deal with local Biotech alone has resulted in nearly 40 authorized partnership deals between new drugs alone, with the number of deals in the first half of the year approaching the full year of 2019.
similar to Roche's innovation center in Zhangjiang and Bayer's china research and development center for healthy consumer goods in Jiangsu will be almost monthly in 2019, especially in the first half of 2020.
in addition to the domestic layout of innovative drugs, foreign pharmaceutical companies have more, more secure choice is to find a new way out of the market outside the hospital.
recent years, prescription out-of-the-way driving, for many pharmaceutical companies to provide market space.
, Pfizer, Bayer, AstraZeneta and other multinational pharmaceutical companies have also set up specialized market teams, targeting the grass-roots market and prescription outflow.
in the prescription outflow market, the chain of pharmacies, DTP pharmacies known for its specialized services, is the choice of many multinational pharmaceutical companies.
Bayer, for example, has long been teaming up with pharmacies to try to achieve win-win marketing for both brands.
Also on July 9, 2019, the two sides will give full play to their respective advantages in the field of medical health and the Internet, build a one-stop operating platform from enterprise to terminal sales, and jointly create a new type of real-time interactive, open and accessable ecology, focusing on the "sinking market" services.
August 24, 2020, Ipson China signed a strategic cooperation agreement with Qingdao Baiyang Pharmaceuticals, a subsidiary of Baiyang Pharmaceuticals, in which the two companies will carry out multi-channel cooperation to meet China's medical needs in the field of intestinal preparation.
, at a critical time for the pharmaceutical industry, companies from all sides are looking for a way forward.
the market segment is more obvious, both multinationals and domestic pharmaceutical companies are re-selecting new tracks to race according to the situation.
In this regard, industry experts predict that five years later in the pharmaceutical market will be the main source of profits of innovative drugs, is the core battleground of pharmaceutical companies;